Faes Farma SA
Faes Farma, S.A., researches, develops, produces, and markets pharmaceutical products, healthcare products, and raw materials internationally. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments. The company also engages in chemical and pharmaceutical products, foodstuffs, cosmetics, dietetics and medicinal… Read more
Faes Farma SA - Asset Resilience Ratio
Faes Farma SA (FAE) has an Asset Resilience Ratio of 0.95% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2000–2025)
This chart shows how Faes Farma SA's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Faes Farma SA's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €12.78 Million | 0.95% |
| Total Liquid Assets | €12.78 Million | 0.95% |
Asset Resilience Insights
- Limited Liquidity: Faes Farma SA maintains only 0.95% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Faes Farma SA Industry Peers by Asset Resilience Ratio
Compare Faes Farma SA's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Kamada
NASDAQ:KMDA |
Drug Manufacturers - Specialty & Generic | 21.63% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp.
KO:000100 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma Inc
KO:000227 |
Drug Manufacturers - Specialty & Generic | 1.74% |
Annual Asset Resilience Ratio for Faes Farma SA (2000–2025)
The table below shows the annual Asset Resilience Ratio data for Faes Farma SA.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.95% | €12.78 Million | €1.34 Billion | +0.02pp |
| 2024-12-31 | 0.93% | €7.92 Million | €853.08 Million | -0.76pp |
| 2023-12-31 | 1.69% | €13.10 Million | €776.03 Million | -9.90pp |
| 2022-12-31 | 11.59% | €84.10 Million | €725.67 Million | +0.15pp |
| 2021-12-31 | 11.44% | €73.41 Million | €641.76 Million | -5.07pp |
| 2020-12-31 | 16.51% | €93.14 Million | €564.15 Million | +16.24pp |
| 2019-12-31 | 0.27% | €1.33 Million | €493.67 Million | +0.19pp |
| 2018-12-31 | 0.08% | €371.00K | €480.80 Million | +0.06pp |
| 2017-12-31 | 0.02% | €70.00K | €430.24 Million | -2.15pp |
| 2016-12-31 | 2.17% | €7.18 Million | €331.22 Million | -0.36pp |
| 2015-12-31 | 2.53% | €7.36 Million | €290.68 Million | +0.08pp |
| 2014-12-31 | 2.45% | €6.55 Million | €267.23 Million | +0.10pp |
| 2013-12-31 | 2.35% | €6.71 Million | €285.16 Million | +0.40pp |
| 2012-12-31 | 1.95% | €5.60 Million | €286.84 Million | -0.23pp |
| 2011-12-31 | 2.18% | €6.34 Million | €291.12 Million | -1.26pp |
| 2010-12-31 | 3.44% | €10.22 Million | €297.10 Million | -1.41pp |
| 2009-12-31 | 4.85% | €11.45 Million | €235.97 Million | +1.42pp |
| 2008-12-31 | 3.43% | €9.44 Million | €275.01 Million | -2.24pp |
| 2007-12-31 | 5.67% | €15.45 Million | €272.43 Million | -1.47pp |
| 2006-12-31 | 7.14% | €16.59 Million | €232.43 Million | +0.66pp |
| 2005-12-31 | 6.48% | €13.99 Million | €216.04 Million | -0.67pp |
| 2004-12-31 | 7.15% | €14.25 Million | €199.29 Million | +0.98pp |
| 2003-12-31 | 6.17% | €12.21 Million | €198.01 Million | -4.20pp |
| 2002-12-31 | 10.36% | €18.33 Million | €176.91 Million | -8.59pp |
| 2001-12-31 | 18.95% | €4.66 Billion | €24.57 Billion | -1.16pp |
| 2000-12-31 | 20.12% | €4.87 Billion | €24.21 Billion | -- |